Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Somewhat Bullish +35

$NVO Stock Bull Case: Novo Nordisk's Wegovy Pill Turnaround

📉 Novo Nordisk guided to adjusted sales declines of 4% to 12% for 2026 due to U.S. pricing pressure and competition from Eli Lilly.

💊 The company launched the first oral GLP-1 for weight management, Wegovy tablets, which surpassed three million prescriptions in approximately five months.

🇪🇺 European regulators approved the Wegovy pill for adults with obesity or qualifying overweight following the OASIS 4 program.

💉 Novo Nordisk launched a higher-dose 7.2-milligram Wegovy injection (Wegovy HD) to improve efficacy against competitors like Zepbound.

🩸 The FDA approved Awiqli, the first once-weekly basal insulin for adults with type 2 diabetes, expected to launch in the second half of 2026.

📊 Q1 2026 reported sales increased 32% at constant exchange rates but underlying adjusted sales declined 4% excluding a one-time provision reversal.

🔬 CagriSema failed its primary head-to-head endpoint against tirzepatide in the REDEFINE 4 trial, though it remains a potential first-in-class combination therapy.

💰 The stock trades at approximately 12.1 times 2025 adjusted earnings, reflecting a significant de-rating from previous monopoly valuations.

📅 Novo Nordisk is scheduled to report first-half 2026 results on August 5, providing a key test for the stabilization thesis.

🌍 International launches in Europe and other regions are expected to begin in the second half of 2026 to diversify revenue streams.

Bullish Signals
  • Wegovy tablets achieved three million paid prescriptions in roughly five months, indicating strong initial demand for the new oral formulation.
  • European Commission approval for the Wegovy pill expands the addressable market beyond the U.S. and validates the product globally.
  • The launch of Wegovy HD (7.2 mg) offers a higher-efficacy option with 20.7% mean weight loss, providing a competitive defense against Eli Lilly's Zepbound.
  • Awiqli approval represents a successful diversification into diabetes care with a convenient once-weekly dosing schedule for basal insulin.
  • The company maintains a robust manufacturing network and global commercial infrastructure that competitors cannot replicate overnight.
  • Novo Nordisk authorized a DKK 15 billion share-repurchase program for 2026, signaling confidence in capital allocation despite the reset.
Risk Factors
  • U.S. adjusted sales declined 11% in Q1 2026 as lower realized prices outweighed volume growth across the Wegovy portfolio.
  • Management has officially guided to negative adjusted sales and operating profit growth of 4% to 12% for full-year 2026.
  • CagriSema failed its primary endpoint in the REDEFINE 4 trial, failing to demonstrate non-inferiority to tirzepatide after 84 weeks.
  • Structural U.S. pricing pressure is expected to continue, with plans announced to reduce list prices of several semaglutide products in 2027.
  • European pricing and reimbursement environments are historically more restrictive than the U.S., potentially limiting initial revenue ramp for new launches.
  • The company faces a formidable competitor in Eli Lilly with superior efficacy data from Zepbound and its own oral obesity program.
Full Analysis
Novo Nordisk (NVO) faces a significant market reset in 2026, characterized by declining U.S. pricing, intense competition from Eli Lilly, and a pipeline setback with CagriSema missing its primary endpoint. Consequently, the company has guided to adjusted sales declines of 4% to 12% for the full year. Despite these headwinds, the stock has fallen to a low-teens earnings multiple, creating a potential contrarian opportunity if the market overreacts to temporary challenges rather than viewing them as permanent structural damage. The primary bullish thesis centers on the successful launch of the first oral GLP-1 for weight management, Wegovy tablets. The product achieved a milestone of three million prescriptions in roughly five months and received European approval. Additionally, Novo launched a higher-dose 7.2-milligram Wegovy injection (Wegovy HD) to compete with Eli Lilly's Zepbound, demonstrating roughly 20.7% mean weight loss in trials. The company also secured U.S. approval for Awiqli, the first once-weekly basal insulin, expanding its diabetes franchise. Investors are advised to focus on the August 5, 2026 earnings report as a critical checkpoint to validate whether pill prescriptions translate into durable revenue and if management can defend its outlook amidst price pressure. The bull case relies on stabilization of the core business, expansion of the treated population via oral options, and the conversion of regulatory approvals into reported revenue, proving that 2026 is a reset year rather than the start of permanent decline.